Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Suspected diagnosis of NASH, evidenced by elevated alanine aminotransferase (ALT), liver stiffness compatible with F2 or F3 fibrosis and Liver Fat Content (LFC) ≥10% as measured by MRI~* Women of childbearing potential and male patients with female partners must agree to use a dual method of contraception~Exclusion Criteria:~* Evidence of worsening liver injury~* Previous diagnosis of other forms of non-NASH liver disease~* Use of Vitamin E, glitazones, glucagon-like Peptide-1 receptor agonists, ursodeoxycholic acid, or obeticholic acid within 90 days prior to screening~* History of cirrhosis or liver decompensation~* Known history of alcohol abuse or daily heavy alcohol consumption~* Pregnant or breastfeeding women~* Type 1 diabetes mellitus and uncontrolled type 2 diabetes mellitus~* Patients with contraindications to MRI imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vonafexor 100 mg BID (Type: EXPERIMENTAL): Oral dose twice daily for 12 weeks (84 days)
- Vonafexor 200 mg QD (Type: EXPERIMENTAL): Oral dose once daily for 12 weeks (84 days)
- Vonafexor 400 mg QD (Type: EXPERIMENTAL): Oral dose once daily for 12 weeks (84 days)
- Placebo (Type: PLACEBO_COMPARATOR): Oral dose twice daily for 12 weeks (84 days)
- Vonafexor 100 mg QD (Type: EXPERIMENTAL): Oral dose once daily for 12 weeks (84 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).